How have ALLR shares performed in 2024?

Allarity Therapeutics' stock was trading at $11.0220 at the beginning of 2024. Since then, ALLR shares have decreased by 86.4% and is now trading at $1.50. View the best growth stocks for 2024 here .

Are investors shorting Allarity Therapeutics?

Allarity Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 25,200 shares, a drop of 95.9% from the March 15th total of 614,300 shares. Based on an average daily volume of 32,500 shares, the days-to-cover ratio is presently 0.8 days. Approximately 9.2% of the shares of the company are short sold. View Allarity Therapeutics' Short Interest .

When is Allarity Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALLR earnings forecast .

When did Allarity Therapeutics' stock split?

Allarity Therapeutics's stock reverse split before market open on Tuesday, April 9th 2024. The 1-20 reverse split was announced on Tuesday, April 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Allarity Therapeutics?

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALLR

Allarity Therapeutics (ALLR) Stock Price, News & Analysis

→ IRS Loophole Gives Americans An Escape From Inflation (From Birch Gold) (Ad)

Free ALLR Stock Alerts

$1.42

-0.08 (-5.33%)

(As of 10:03 AM ET)

Compare

Today's Range: $1.38
▼
$1.50
50-Day Range: $1.50
▼
$8.80
52-Week Range: $1.38
▼
$628.00

Volume: 225,536 shs
Average Volume: 392,407 shs
Market Capitalization: $440,200.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Allarity Therapeutics alerts:

Allarity Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
9.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($28.60) to ($30.40) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.15 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Allarity Therapeutics.

4.0

Short Interest

Percentage of Shares Shorted
9.18% of the float of Allarity Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Allarity Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Allarity Therapeutics has recently decreased by 95.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Allarity Therapeutics does not currently pay a dividend.
Dividend Growth
Allarity Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALLR.

2.3

News and Social Media Coverage

News Sentiment
Allarity Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Allarity Therapeutics this week, compared to 1 article on an average week.
Search Interest
9 people have searched for ALLR on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.08% of the stock of Allarity Therapeutics is held by insiders.
Percentage Held by Institutions
Only 11.53% of the stock of Allarity Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Allarity Therapeutics are expected to decrease in the coming year, from ($28.60) to ($30.40) per share.

See Top Rated MarketRank™ Stocks Here

Ad Birch Gold

IRS Loophole Gives Americans An Escape From Inflation

In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.

Request your info kit on gold now

About Allarity Therapeutics Stock (NASDAQ:ALLR)

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

ALLR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALLR Stock News Headlines

April 17, 2024 | finanznachrichten.de

Allarity Therapeutics, Inc.: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)

April 17, 2024 | finance.yahoo.com

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

April 18, 2024 | Birch Gold (Ad)

IRS Loophole Gives Americans An Escape From Inflation

April 17, 2024 | globenewswire.com

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

April 12, 2024 | investorplace.com

Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?

April 4, 2024 | finanznachrichten.de

Allarity Therapeutics, Inc.: Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

April 4, 2024 | msn.com

Allarity Therapeutics to implement 1-for-20 reverse stock split

April 4, 2024 | globenewswire.com

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

April 18, 2024 | Birch Gold (Ad)

IRS Loophole Gives Americans An Escape From Inflation

March 27, 2024 | globenewswire.com

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

March 25, 2024 | globenewswire.com

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

March 8, 2024 | finanznachrichten.de

Allarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

March 8, 2024 | benzinga.com

Allarity Therapeutics: Q4 Earnings Insights

March 8, 2024 | globenewswire.com

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

February 28, 2024 | globenewswire.com

Allarity Therapeutics to Present at Biomarkers 2024

February 23, 2024 | benzinga.com

Allarity Therapeutics Stock (NASDAQ:ALLR), Short Interest Report

February 23, 2024 | benzinga.com

Allarity Therapeutics Stock (NASDAQ:ALLR) Dividends: History, Yield and Dates

February 2, 2024 | bizjournals.com

Boston biotech loses Novartis drug license agreement for nonpayment

February 2, 2024 | msn.com

Allarity Therapeutics’ Licensing Agreement with Novartis Terminated

December 12, 2023 | markets.businessinsider.com

Allarity Therapeutics CEO James Cullem Steps Down

December 12, 2023 | finance.yahoo.com

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

December 7, 2023 | finance.yahoo.com

ALLR: Stenoparib Clinical Update

December 6, 2023 | seekingalpha.com

Allarity stock soars 60% premarket on ovarian cancer therapy results

December 5, 2023 | investorplace.com

Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today?

December 5, 2023 | markets.businessinsider.com

Allarity's Early Phase 2 Stenoparib Data Suggests Encouraging Results In Advanced Ovarian Cancer

December 5, 2023 | finance.yahoo.com

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

November 10, 2023 | morningstar.com

Allarity Therapeutics Inc ALLR

See More Headlines

Receive ALLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALLR
CUSIP: N/A
CIK: 1860657
Web: www.allarity.com
Phone: 401-426-4664
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,900,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -91.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.14
Quick Ratio: 0.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($18.63) per share
Price / Book: -0.08

Miscellaneous

Outstanding Shares: 309,000
Free Float: 309,000
Market Cap: $463,500.00
Optionable: Not Optionable
Beta: 0.25

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Thomas H. Jensen (Age 46)
Founder, CEO, Senior VP of Investor Relations & Director
Ms. Joan Y. Brown (Age 70)
Interim CFO
Comp: $180k
Dr. Steen Meier Knudsen Ph.D. (Age 63)
Founder & Chief Scientific Officer
Comp: $185.11k

Key Competitors

View All Competitors

ALLR Stock Analysis - Frequently Asked Questions

How have ALLR shares performed in 2024?: Allarity Therapeutics' stock was trading at $11.0220 at the beginning of 2024. Since then, ALLR shares have decreased by 86.4% and is now trading at $1.50.
View the best growth stocks for 2024 here.
Are investors shorting Allarity Therapeutics?: Allarity Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 25,200 shares, a drop of 95.9% from the March 15th total of 614,300 shares. Based on an average daily volume of 32,500 shares, the days-to-cover ratio is presently 0.8 days. Approximately 9.2% of the shares of the company are short sold.
View Allarity Therapeutics' Short Interest.
When is Allarity Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALLR earnings forecast.

When did Allarity Therapeutics' stock split?: Allarity Therapeutics's stock reverse split before market open on Tuesday, April 9th 2024. The 1-20 reverse split was announced on Tuesday, April 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of Allarity Therapeutics?: Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Allarity Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

About Allarity Therapeutics Stock (NASDAQ:ALLR)

ALLR Stock Price History

ALLR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ALLR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™